Resumen
Background: Wearable fitness technologies, like the Oura Ring (Oura Health Oy), provide physiological metrics, like sleep and heart rate data, to a growing user base of young adults. However, these technologies and connected mobile apps do not measure young adults’ alcohol use that contributes to these metrics. Personalized feedback on the impact of alcohol on sleep and heart rate may boost motivation to reduce drinking among young adults. Objective: For this pilot randomized controlled trial, we evaluated the acceptability, feasibility, and perceived effectiveness of a wearable personalized feedback intervention for alcohol reduction in young adults that integrated physiological and behavioral data. Methods: Recruitment took place offline and online via open access websites. Participants (N=60) wore the Oura Ring for 6 weeks and completed daily behavioral smartphone diaries. Only the feedback group (n=30) had full access to the Oura Ring app and personalized feedback reports every 2 weeks, received from the study team. The app included daily feedback on sleep and cardiovascular recovery. Feedback reports combined Oura Ring and diary data to show trends of alcohol use alongside sleep and cardiovascular data. We used artificial intelligence–driven convergent mixed methods to evaluate self-assessed exit surveys and face-to-face exit interviews, including natural language processing and researcher-coded qualitative analyses with interviews. Results: Half of participants (30/60, 50%) were men, 81.6% (49/60) were White, and they had a mean age of 22.02 (SD 1.98) years. Across both groups, the overall program was described as highly acceptable, feasible, and effective. Wearing the Oura Ring was highly acceptable and feasible. The smartphone diaries were moderately acceptable, moderately-highly feasible, and highly effective. The feedback reports were highly acceptable, feasible, and effective. Among feedback group participants, the Oura Ring and app were moderately effective. The feedback group participants also had high adherence using the app daily, and 80% (48/60) read all 3 feedback reports. Per natural language processing, the most common topic in the feedback interviews related to their behavior change due to multiple intervention components (Ɵk=0.18). This contrasted with the most common topic from assessment group participants about prechange learning (Ɵk=0.22). During the researcher-coded qualitative analysis, we identified themes in 3 categories. Most participants described helpful aspects of the Oura Ring and app, smartphone diaries, and feedback report. Most felt that the report had the right amount of information, and a large group reported they learned about their sleep deficits. Curiosity was the most common reason participants joined the study. SMS text messages and usability kept them engaged, and almost none considered dropping out. Conclusions: Commercial fitness wearables that integrate behavioral data may be acceptable and feasible and promote readiness to change drinking in young adults who are generally unconcerned about risky behaviors.
| Idioma original | English |
|---|---|
| Número de artículo | e78613 |
| Publicación | Journal of Medical Internet Research |
| Volumen | 27 |
| N.º | 1 |
| DOI | |
| Estado | Published - 2025 |
Nota bibliográfica
Publisher Copyright:© Frances J Griffith, Oksana K Ellison, Sahiti Kunchay, Madilyn Augustine, Kelly S DeMartini, Michael Fatigate, Leah Latimer, Stephanie S O'Malley, Nancy S Redeker, Garrett I Ash, Lisa M Fucito.
Financiación
The authors attest that no external sponsors had influence on the design of this study, its outcomes, or the decision to publish. FJG is an unpaid consultant for Calm Health. KSD reports a provisional patent file for a digital system for lifestyle medicine (47162-5346-P1US), and registration of the name and content of the Call it a Night web-based sleep program with the U.S. Patent and Trademark Office (since expired). SSO reports being a member of the American Society of Clinical Psychopharmacology’s (ASCP) Alcohol Clinical Trials Initiative, supported by Alkermes, Dicerna, Eli Lilly and Company, Ethypharm, Indivior, Imbrium Therapeutics, Osuka, Pear Therapeutics, and Kinnov Therapeutics; consultant/advisory board member, Dicerna, Eli Lilly and Company, Newleos Therapeutics, University of New Mexico (NIH grant); stock options, Newleos Therapeutics; medication supplies, Novar-tis/Stalicla, Amygdala; contracts, Tempero Bio, Altimmune; DSMB member, Emmes Corporation, Indiana University; patent application on mavoglurant for gambling disorder with Novartis and Yale; and grants from the NIH and FDA. GIA is a scientific advisor to Behavioral Health Tech Innovations LLC. GIA receives professional services from Calm.com (nominal fee), Labfront (full fee), and GlucoseZone (full fee). GIA reports a provisional patent filed for a digital system for lifestyle medicine (047162–5346-P1US). GIA in the past 5 years has been supported by a VHA Office of Academic Affiliations Fellowship, Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award, Bank of America, N.A., Trustee, and American Heart Association Grant #852679 (2021-2024). LMF reports grant funding from the US National Institutes of Health to directly support the research (R21AA028886), a provisional patent file for a digital system for lifestyle medicine (47162-5346-P1US), registration of the name and content of the Call it a Night web-based sleep program with the U.S. Patent and Trademark Office (since expired), and paid consultation for serving on an advisory board for Imbrium Therapeutics. All other authors report no disclosures. This research was directly supported by a grant from the National Institute on Alcohol Abuse and Alcoholism under award number R21AA028886. Additional grants from the National Institutes of Health that supported effort are as follows: T32DA019426 (FJG), T32DA007238 (OKE), K01DK129441 (GIA), and R01AA030136.
| Financiadores | Número del financiador |
|---|---|
| Kinnov Therapeutics | |
| New Mexico State University, New York University | |
| American Society of Clinical Psychopharmacology’s | |
| FDA‐OPD | |
| The EMMES Corporation | |
| NIH | |
| VHA Office of Academic Affiliations Fellowship | |
| University of Southern Indiana | |
| National Institutes of Health (NIH) | 47162-5346-P1US, T32DA019426, T32DA007238, R01AA030136, K01DK129441 |
| National Institute on Alcohol Abuse and Alcoholism | R21AA028886 |
| American the American Heart Association | 852679, 2021-2024 |
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
Good health and well being
ASJC Scopus subject areas
- Health Informatics
Huella
Profundice en los temas de investigación de 'Oura Ring Behavioral Feedback Intervention for Alcohol Reduction in Young Adults: User Experience Evaluation of a Pilot Randomized Trial'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver